Kaken Pharmaceuticals Co., Ltd.

14 articles about Kaken Pharmaceuticals Co., Ltd.

• CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis

  1/8/2023

  CymaBay Therapeutics, Inc. announced that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization in Japan of CymaBay’s investigational drug seladelpar for the treatment of primary biliary cholangitis.

• Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan

  1/5/2023

  Spruce Biosciences, Inc. and Kaken Pharmaceutical Co. Ltd announced that the companies have entered into an exclusive licensing agreement for the development and commercialization of Spruce’s product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia in Japan.

• MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan

  12/23/2022

  MediWound Ltd. today announced that its partner, Kaken Pharmaceutical Co., Ltd. has gained marketing approval of NexoBrid® in Japan.

• Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

  6/24/2021

  Brickell Biotech, Inc. today announced that its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”), recently initiated a Phase 1 clinical study to assess the pharmacokinetics (PK) of sofpironium bromide gel in patients with primary palmoplantar hyperhidrosis (PPH) in Japan.

• Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical

  11/18/2020

  Kaken plans to launch ECCLOCK®for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020

• Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical

  6/15/2020

  Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis

• HitGen and Kaken Enter Into License Agreement

  4/11/2019

  HitGen Inc. announced today that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs.

• Perrigo Confirms Patent Challenge for Generic Version of Jublia® Topical Solution 10%

  10/1/2018

  Perrigo Company plc today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken Pharmaceuticals Co., LTD, initiated patent litigation on September 21, 2018 in the United States District Court for the District

• 

  FDA Hits Valeant’s Plaque Psoriasis Drug with a Complete Response Letter

  6/19/2018

  Ortho Dermatologics, a division of Quebec-based Valeant Pharmaceuticals International, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Duobrii for plaque psoriasis.

• Numab AG And Kaken Pharmaceuticals Enter Into A Collaboration And Option Agreement

  6/13/2017

• Brickell Biotech Signs Exclusive License And Development Agreement For BBI-4000 With Kaken Pharmaceuticals

  4/1/2015

• Kaken Pharmaceuticals and ChemDiv, Inc. Partner in Drug Discovery Deal

  2/26/2007

• Kaken Pharmaceuticals To License Its Antifungal Compound KP-103 To Dow Pharmaceutical Sciences

  5/11/2006

• Kaiser Health Plan And Hospitals Continue Solid Financial Performance

  7/30/2004